Cargando…

ZR-75-1 breast cancer models to study the utility of (18)F-FES by PET imaging

BACKGROUND: Breast cancer is a hormone-dependent tumor, and 70–80% of breast cancer patients are estrogen receptor (ER) positive. ZR-75-1 cell lines are more consistent with human breast cancer, which is mostly ER positive and PR positive. To better study the biological characteristics of (18)F-fluo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Ziteng, Xu, Xudang, Li, Tiannv, Wang, Jia, Sun, Jin, Tang, Lijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797387/ https://www.ncbi.nlm.nih.gov/pubmed/35116468 http://dx.doi.org/10.21037/tcr-20-3228

Ejemplares similares

Prognostic value of baseline total metabolic tumour volume of (18)F-FDG PET/CT imaging in patients with angioimmunoblastic T-cell lymphoma
por: Gong, Huanyu, et al.
Publicado: (2021)

Image Quality and Interpretation of [(18)F]-FES-PET: Is There any Effect of Food Intake?
por: Boers, Jorianne, et al.
Publicado: (2020)

Analyzing the Estrogen Receptor Status of Liver Metastases with [(18)F]-FES-PET in Patients with Breast Cancer
por: Boers, Jorianne, et al.
Publicado: (2021)

Visual and quantitative evaluation of [(18)F]FES and [(18)F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study
por: Mammatas, Lemonitsa H., et al.
Publicado: (2020)

Evaluation of estrogen expression of breast cancer using (18)F-FES PET CT-A novel technique
por: Seenu, Vuthaluru, et al.
Publicado: (2020)

Comparison of (18)F-FES, (18)F-FDG, and (18)F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer
por: He, SiMin, et al.
Publicado: (2016)

(18)F-FDG/(18)F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma
por: Yamamoto, Makoto, et al.
Publicado: (2017)

Head-to-Head Comparison between (18)F-FES PET/CT and (18)F-FDG PET/CT in Oestrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-Analysis
por: Piccardo, Arnoldo, et al.
Publicado: (2022)

Utility of [18F]-fluoroestradiol (FES) PET/CT with dedicated brain acquisition in differentiating brain metastases from posttreatment change in estrogen receptor-positive breast cancer
por: Ivanidze, Jana, et al.
Publicado: (2021)

A preliminary study of (18)F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel
por: Gong, Chengcheng, et al.
Publicado: (2017)

[(18)F]FES PET Resolves the Diagnostic Dilemma of COVID-19-Vaccine-Associated Hypermetabolic Lymphadenopathy in ER-Positive Breast Cancer
por: Nogami, Munenobu, et al.
Publicado: (2023)

[(18)F]FES uptake in the pituitary gland and white matter of the brain
por: Iqbal, R., et al.
Publicado: (2021)

Enhanced pulmonary uptake on (18)F-FES-PET/CT scans after irradiation of the thoracic area: related to fibrosis?
por: Venema, C. M., et al.
Publicado: (2019)

Investigation of (18)F and (89)Zr Isotopes Self-Absorption and Dose Rate Parameters for PET Imaging
por: Alfuraih, Abdulrahman A., et al.
Publicado: (2021)

18F-FES PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive Breast Cancer: Two Representative Cases and Review of the Literature
por: Bodapati, Sandhya, et al.
Publicado: (2022)

The added prognostic values of baseline PET dissemination parameter in patients with angioimmunoblastic T‐cell lymphoma
por: Gong, Huanyu, et al.
Publicado: (2022)

Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal (18)F-FES PET/CT
por: He, SiMin, et al.
Publicado: (2019)

Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by (18)F-FES PET
por: Xie, Yizhao, et al.
Publicado: (2022)

Clinical Utility of Pre-Therapeutic [18F]FDG PET/CT Imaging for Predicting Outcomes in Breast Cancer
por: Najid, Sophia, et al.
Publicado: (2023)

Performance of nanoScan PET/CT and PET/MR for quantitative imaging of (18)F and (89)Zr as compared with ex vivo biodistribution in tumor-bearing mice
por: Chomet, Marion, et al.
Publicado: (2021)

PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging
por: Katzenellenbogen, John A.
Publicado: (2020)

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using (18)F-FES PET/CT imaging
por: Jager, Agnes, et al.
Publicado: (2020)

An In Vitro and In Vivo Evaluation of a Reporter Gene/Probe System hERL/(18)F-FES
por: Qin, Chunxia, et al.
Publicado: (2013)

Utility of 18F FDG-PET in Parkinsonism in an African population
por: Amod, Ferzana Hassan, et al.
Publicado: (2022)

Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2019)

Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer
por: Aogi, Kenjiro, et al.
Publicado: (2015)

Characterisation of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and ability of the resistant phenotype.
por: van den Berg, H. W., et al.
Publicado: (1989)

Clinical utility of (18)F-FDG PET/CT imaging in patients with pulmonary artery sarcoma
por: Ren, Jingyun, et al.
Publicado: (2022)

(18)F-Fluciclovine ((18)F-FACBC) PET imaging of recurrent brain tumors
por: Michaud, Laure, et al.
Publicado: (2019)

Current Perspectives on (89)Zr-PET Imaging
por: Yoon, Joon-Kee, et al.
Publicado: (2020)

Automatic Production and Preliminary PET Imaging of a New Imaging Agent [(18)F]AlF-FAPT
por: Huang, JiaWen, et al.
Publicado: (2022)

[(18)F]FDG and [(18)F]FES positron emission tomography for disease monitoring and assessment of anti-hormonal treatment eligibility in granulosa cell tumors of the ovary
por: Roze, Joline F., et al.
Publicado: (2021)

Imaging patients with breast and prostate cancers using combined 18F NaF/18F FDG and TOF simultaneous PET/ MRI
por: Iagaru, Andrei, et al.
Publicado: (2015)

The utility of (18)F-FDG PET/CT in brain tumours diagnosis
por: Pietrzak, Agata, et al.
Publicado: (2022)

(18)F-FDG PET/CT Imaging In Oncology
por: Almuhaideb, Ahmad, et al.
Publicado: (2011)

Extramedullary haematopoiesis imaging with (18)F-FLT PET
por: Agool, Ali, et al.
Publicado: (2010)

(18)F-fluorothymidine PET imaging in gliomas: an update
por: Nikaki, Alexandra, et al.
Publicado: (2017)

Atherosclerosis Imaging with (18)F-Sodium Fluoride PET
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2020)

[(18)F] Clofarabine for PET Imaging of Hepatocellular Carcinoma
por: Sergeeva, Olga, et al.
Publicado: (2019)

Advances in [(18)F]Trifluoromethylation Chemistry for PET Imaging
por: Francis, Felix, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r34l4ltd4kmflocf3momn44lfb